Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
3 other identifiers
interventional
318
23 countries
130
Brief Summary
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression of their disease while receiving aromatase inhibitor (AI) therapy or who have relapsed within 6 months after completing adjuvant AI therapy will be enrolled in Part I of this study. Participants with ABC or MBC who have received prior AI therapy and who have PIK3CA-mutant tumors will be enrolled in Part II of this study. Part I of the study will assess the effect of the addition of GDC-0941 to fulvestrant (Arm A) and of GDC-0980 to fulvestrant (Arm B) on progression free survival (PFS) compared with fulvestrant + placebo (Arm C). Part II of the study will examine the safety and tolerability and to estimate the effect of GDC-0941 in combination with fulvestrant (Arm D) on PFS versus fulvestrant + placebo (Arm E) in participants who received prior treatment with an AI and whose tumors contain a PIK3CA mutation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 breast-cancer
Started Oct 2011
Typical duration for phase_2 breast-cancer
130 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 8, 2011
CompletedFirst Posted
Study publicly available on registry
September 21, 2011
CompletedStudy Start
First participant enrolled
October 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedNovember 2, 2016
November 1, 2016
4.5 years
September 8, 2011
November 1, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
Progression Free Survival as Assessed by the Investigator Per modified RECIST v 1.1
From Screening to up to approximately 5 years (assessed at Screening, after 8, 16, 24 and 32 weeks of treatment, every 12 weeks thereafter until disease progression or initiation of other anti-cancer therapy)
Percentage of Participants with Adverse Events
Baseline to up to 30 days after the last dose of study drug (Approximately 5 years)
Secondary Outcomes (7)
Percentage of Participants with Objective Tumor Response (Complete Response [CR] or Partial Response [PR] as Assessed by the Investigator Per Modified RECIST v 1.1
From Screening to up to approximately 5 years (assessed at Screening, after 8, 16, 24 and 32 weeks of treatment, every 12 weeks thereafter until disease progression or initiation of other anti-cancer therapy)
Percentage of Participants with Clinical Benefit Response Defined as PR, CR, or SD Per Modified RECIST v 1.1
From Screening to up to approximately 5 years (assessed at Screening, after 8, 16, 24 and 32 weeks of treatment, every 12 weeks thereafter until disease progression or initiation of other anti-cancer therapy)
Duration of Confirmed Objective Response as Assessed by the investigator Per Modified RECIST v 1.1
From Screening to up to approximately 5 years (assessed at Screening, after 8, 16, 24 and 32 weeks of treatment, every 12 weeks thereafter until disease progression or initiation of other anti-cancer therapy)
Percentage of Participants with PIK3CA Mutant Tumors
Baseline
Time to Maximum Plasma Concentration (Tmax) of GDC-0941 and GDC-0948
Part 1:0-4 hour (hr) predose (PrD), 1,2,4 hr postdose (PoD) on Day 15 of Cycles 1 & 2, PrD on Cycle 1 Day 16, 0-4 hr PrD & 2 hr PoD on Cycle 6 Day 1; Part II:0-4 hr PrD, 2 hr PoD on Day 1 of Cycles 1 & 6, 0-4 hr PrD, 1, 2, 4 hr PoD on Cycle 2 Day 1
- +2 more secondary outcomes
Study Arms (5)
GDC-0941 Matching Placebo + Fulvestrant (Arm E)
PLACEBO COMPARATORParticipants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
GDC-0941-260 mg + Fulvestrant (Arm D)
EXPERIMENTALParticipants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
GDC-0941-340 mg + Fulvestrant (Arm A)
EXPERIMENTALParticipants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)
PLACEBO COMPARATORParticipants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
GDC-0980-30 mg + Fulvestrant (Arm B)
EXPERIMENTALParticipants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Interventions
Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Eligibility Criteria
You may qualify if:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- As per national or local treatment guidelines, endocrine therapy (i.e., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not necessary for participants, at time of entry into the study.
- Part I: Postmenopausal women with locally ABC or MBC whose disease relapsed during treatment with (or within 6 months after discontinuation of) an AI in the adjuvant setting or progressed during treatment with an AI in the metastatic setting.
- Part II: Postmenopausal women with locally ABC or MBC whose disease has progressed during or after treatment with an AI. Participants who discontinued the AI for toxicity rather than completion of regimen or for disease progression are not eligible
- Estrogen receptor (ER)-positive disease and human epidermal receptor 2 (HER2)-negative disease
- Participants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scans
- Adequate hematologic and end-organ function
You may not qualify if:
- Prior treatment with fulvestrant, phosphoinositide 3-kinase (PI3K) inhibitor, or mechanistic target of rapamycin (mTOR) inhibitor for ABC or MBC
- Prior anti-cancer therapy or radiotherapy within 2 weeks prior to Day 1 of Cycle 1
- Prior treatment with greater than (\>) one cytotoxic chemotherapy regimens or experienced recurrent or progressive disease on \> two endocrine therapies for MBC
- Participants requiring anti-hyperglycemic therapy
- Clinically significant cardiac or pulmonary dysfunction
- History of malabsorption syndrome or other condition that would interfere with enteral absorption
- Clinically significant history of liver disease
- Active uncontrolled autoimmune disease or active inflammatory disease
- Immunocompromised status
- Need for current chronic corticosteroid therapy
- Pregnancy, lactation, or breastfeeding
- Current severe, uncontrolled systemic disease
- Symptomatic hypercalcemia
- Known untreated or active central nervous system (CNS) metastases
- History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or patients who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Genentech, Inc.lead
Study Sites (130)
Unknown Facility
Birmingham, Alabama, 35294, United States
Unknown Facility
Hayward, California, 94545, United States
Unknown Facility
Oakland, California, 94611, United States
Unknown Facility
Roseville, California, 95661, United States
Unknown Facility
Sacramento, California, 95825, United States
Unknown Facility
San Francisco, California, 94115, United States
Unknown Facility
San Jose, California, 95119, United States
Unknown Facility
Santa Clara, California, 95051, United States
Unknown Facility
South San Francisco, California, 94080, United States
Unknown Facility
Vallejo, California, 94589, United States
Unknown Facility
Walnut Creek, California, 94596, United States
Unknown Facility
Washington D.C., District of Columbia, 20010, United States
Unknown Facility
Boca Raton, Florida, 33428, United States
Unknown Facility
Fort Myers, Florida, 33916, United States
Unknown Facility
Jacksonville, Florida, 32224, United States
Unknown Facility
St. Petersburg, Florida, 33705, United States
Unknown Facility
Marietta, Georgia, 30060, United States
Unknown Facility
Joliet, Illinois, 60435, United States
Unknown Facility
Peoria, Illinois, 61615, United States
Unknown Facility
Wichita, Kansas, 67214-3728, United States
Unknown Facility
Boston, Massachusetts, 02115, United States
Unknown Facility
Boston, Massachusetts, 02215, United States
Unknown Facility
St Louis, Missouri, 63128, United States
Unknown Facility
Basking Ridge, New Jersey, 07920, United States
Unknown Facility
Hackensack, New Jersey, 07601, United States
Unknown Facility
Commack, New York, 11725, United States
Unknown Facility
New York, New York, 10065, United States
Unknown Facility
Rockville Centre, New York, 11570, United States
Unknown Facility
Sleepy Hollow, New York, 10591, United States
Unknown Facility
Philadelphia, Pennsylvania, 19104, United States
Unknown Facility
Charleston, South Carolina, 29425, United States
Unknown Facility
Chattanooga, Tennessee, 37404, United States
Unknown Facility
Germantown, Tennessee, 38138, United States
Unknown Facility
Nashville, Tennessee, 37211, United States
Unknown Facility
Nashville, Tennessee, 37232, United States
Unknown Facility
Dallas, Texas, 75246, United States
Unknown Facility
Fort Worth, Texas, 76104, United States
Unknown Facility
Houston, Texas, 77030-4095, United States
Unknown Facility
Houston, Texas, 77030, United States
Unknown Facility
Tyler, Texas, 75702, United States
Unknown Facility
Richmond, Virginia, 23226, United States
Unknown Facility
Buenos Aires, 1025, Argentina
Unknown Facility
Santa Fe, 03000, Argentina
Unknown Facility
Kogarah, New South Wales, 2217, Australia
Unknown Facility
Wahroonga, New South Wales, 2076, Australia
Unknown Facility
South Brisbane, Queensland, 4101, Australia
Unknown Facility
Bedford Park, South Australia, 5042, Australia
Unknown Facility
Woodville, South Australia, 5011, Australia
Unknown Facility
Frankston, Victoria, 3199, Australia
Unknown Facility
Parkville, Victoria, 3050, Australia
Unknown Facility
Brussels, 1000, Belgium
Unknown Facility
Brussels, 1070, Belgium
Unknown Facility
Edegem, 2650, Belgium
Unknown Facility
Leuven, 3000, Belgium
Unknown Facility
Liège, 4000, Belgium
Unknown Facility
Montreal, Quebec, H3G 1A4, Canada
Unknown Facility
Québec, Quebec, G1R 2J6, Canada
Unknown Facility
Saskatoon, Saskatchewan, S7N 4H4, Canada
Unknown Facility
Santiago, 7630370, Chile
Unknown Facility
Temuco, 4810469, Chile
Unknown Facility
Valparaíso, 2341391, Chile
Unknown Facility
Viña del Mar, 2540364, Chile
Unknown Facility
Brno, 656 53, Czechia
Unknown Facility
Olomouc, 775 20, Czechia
Unknown Facility
Prague, 128 08, Czechia
Unknown Facility
Aarhus, 8000, Denmark
Unknown Facility
Herlev, 2730, Denmark
Unknown Facility
København Ø, 2100, Denmark
Unknown Facility
Odense, 5000, Denmark
Unknown Facility
Roskilde, 4000, Denmark
Unknown Facility
Vejle, 7100, Denmark
Unknown Facility
Paris, 75231, France
Unknown Facility
Berlin, 13125, Germany
Unknown Facility
Düsseldorf, 40225, Germany
Unknown Facility
Freiburg im Breisgau, 79106, Germany
Unknown Facility
Freiburg im Breisgau, 79110, Germany
Unknown Facility
Hamburg, 20246, Germany
Unknown Facility
München, 80336, Germany
Unknown Facility
München, 81377, Germany
Unknown Facility
München, 81675, Germany
Unknown Facility
Trier, 54290, Germany
Unknown Facility
Hong Kong, 852, Hong Kong
Unknown Facility
Pokfulam, Hong Kong
Unknown Facility
Beersheba, 8410101, Israel
Unknown Facility
Holon, 58100, Israel
Unknown Facility
Jerusalem, 91120, Israel
Unknown Facility
Jerusalem, 9372212, Israel
Unknown Facility
Kfar Saba, 4428164, Israel
Unknown Facility
Rehovot, 7610001, Israel
Unknown Facility
Tel Aviv, 6423906, Israel
Unknown Facility
Tel Litwinsky, 52621, Israel
Unknown Facility
Ẕerifin, 70300, Israel
Unknown Facility
Napoli, Campania, 80131, Italy
Unknown Facility
Meldola, Emilia-Romagna, 47014, Italy
Unknown Facility
Milan, Lombardy, 20121, Italy
Unknown Facility
Milan, Lombardy, 20132, Italy
Unknown Facility
Milan, Lombardy, 20141, Italy
Unknown Facility
Monza, Lombardy, 20900, Italy
Unknown Facility
Pisa, Tuscany, 56100, Italy
Unknown Facility
Prato, Tuscany, 59100, Italy
Unknown Facility
Terni, Umbria, 05100, Italy
Unknown Facility
George Town, 10050, Malaysia
Unknown Facility
George Town, 10400, Malaysia
Unknown Facility
Kuala Lumpur, 56000, Malaysia
Unknown Facility
Kuala Lumpur, 59100, Malaysia
Unknown Facility
Tanjung Bungah, 11200, Malaysia
Unknown Facility
León, 37000, Mexico
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Hamilton, 3240, New Zealand
Unknown Facility
Wellington, 0621, New Zealand
Unknown Facility
Lima, 11, Peru
Unknown Facility
Lima, 34, Peru
Unknown Facility
Lima, Lima 27, Peru
Unknown Facility
Chelyabinsk, 454087, Russia
Unknown Facility
Kazan', 420029, Russia
Unknown Facility
Moscow, 115478, Russia
Unknown Facility
Voronezh, 394000, Russia
Unknown Facility
Singapore, 119074, Singapore
Unknown Facility
Seoul, 138-736, South Korea
Unknown Facility
Barcelona, Barcelona, 08035, Spain
Unknown Facility
Lleida, Lerida, 25198, Spain
Unknown Facility
Valencia, Valencia, 46015, Spain
Unknown Facility
Zaragoza, Zaragoza, 50009, Spain
Unknown Facility
Patumwan, 10330, Thailand
Unknown Facility
Songkhla, 90110, Thailand
Unknown Facility
Brighton, BN1 9PX, United Kingdom
Unknown Facility
Cardiff, CF14 2TL, United Kingdom
Unknown Facility
London, SW3 6JJ, United Kingdom
Unknown Facility
London, W1G 6AD, United Kingdom
Unknown Facility
Stoke-on-Trent, ST4 7LN, United Kingdom
Related Publications (1)
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):811-821. doi: 10.1016/S1470-2045(16)00106-6. Epub 2016 May 4.
PMID: 27155741DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Gallia Levy, M.D., Ph.D.
Genentech, Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 8, 2011
First Posted
September 21, 2011
Study Start
October 1, 2011
Primary Completion
April 1, 2016
Study Completion
April 1, 2016
Last Updated
November 2, 2016
Record last verified: 2016-11